Key Highlights: Implications: Zydus is differentiating in a crowded GLP‑1 space with a single reusable multi‑dose pen and 15 mg/3 mL cartridge, simplifying titration and potentia...
Key Highlights: Implications: By pricing its once‑weekly semaglutide at around ₹450 per week via a pre‑filled disposable pen, Alkem is positioning one of the lowest‑cost GLP‑1 op...
Key Highlights: Implications: By launching semaglutide under two differentiated brands with full dose coverage and price points 60%+ below innovator levels, Sun is set to rapidly expand ac...
Key Highlights: Implications: By launching Day‑1 multi‑dose vials at ₹1,290–₹1,750 per month and claiming 70–90% discounts vs pens and innovator brands, Natco is setting the floor on...
Key Highlights: Implications: The partnership lets Zydus scale its semaglutide franchise while tapping Torrent’s strong chronic-care reach, accelerating GLP‑1 penetration without stretchin...
Key Highlights: Implications: The 7-ACA facility directly strengthens India’s antibiotic supply chain by localizing production of a critical cephalosporin KSM, reducing exposure to import ...
Key Highlights: Implications: Lilly’s pricing gamble carves a high-end niche, outpacing semaglutide generics from local players through clinical edge and brand power. This sets up fi...
